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Available online 4 November 2011This study was designed to investigate the protective effects of the combination of guanosine
and 2 organoselenium compounds (ebselen and diphenyl diselenide) against glutamate-
induced oxidative stress in different regions of rat brains. Glutamate caused an increase in
reactive oxygen species (ROS) generation and a decrease in [3H]-glutamate uptake in striatal,
cortical, and hippocampal slices. Guanosine, ebselen, and diphenyl diselenide prevented
glutamate-induced ROS production in striatal, cortical and hippocampal slices. The combina-
tion of guanosine with organoselenium compounds was more effective against glutamate-
induced ROS production than the individual compounds alone. Guanosine prevented [3H]-
glutamate uptake inhibition in striatal, cortical, and hippocampal slices. Thus, protection
against the harmful effects of glutamate is possibly due to the combination of the antioxidant
properties of organoselenium compounds and the stimulatory effect of guanosine on gluta-
mate uptake. In conclusion, the combination of antioxidants and glutamatergic systemmod-
ulators could be considered a potential therapy against the prooxidant effects of glutamate.






The amino acid L-glutamate is the predominant excitatory
neurotransmitter in the central nervous system (CNS) of
mammals (Gilgun-Sherki et al., 2002; McEntee and Crook,
1993). After being released in the synaptic cleft, L-glutamate
must be removed quickly and efficiently from the extracellu-
lar fluid by high-affinity transporters to avoid receptor8.
res).




 the Elsevier OA license.overstimulation (Danbolt, 2001; Trotti et al., 1998; Walton
and Dodd, 2007). The glutamate transporters in the plasma
membranes of both astrocytes and neurons perform this
task (Trotti et al., 1998). These glutamate transporters have
an important role in terminating synaptic transmission, as
sustained elevation of extracellular glutamate triggers neuro-
nal death through a mechanism termed excitotoxicity (Choi,
1992; Mejia-Toiber et al., 2006).us system; GPx, glutathione peroxidase; TBARS, thiobarbituric
azolium bromide; LDH, lactate dehydrogenase; DCFH, 2′,7′-dichloro-
; TBA, thiobarbituric acid; MDA, malondialdehyde; DMSO, dimethyl-
β-nicotinamide adenine dinucleotide
Table 1 – Effect of glutamate on lipid peroxidation.
Glutamate (mM) TBARS production (% control)
Striatum Cortex Hippocampus
0 100±8.2 103.4±1.7 96±4.2
0.01 81.5±5.4 93.9±1.9 117.5±4.2
0.1 96±1.6 100.9±3.8 101.2±0.8
1 100.4±5.8 102.5±2.9 125±5.9
10 104.1±4.4 134.5±11.6 ⁎ 148.7±18.1 ⁎
Data are mean±SEM for n=4–5 in each group.
⁎ p<0.05 compared to control.
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ders such as epilepsy, ischemia, trauma, amyotrophic lateral
sclerosis, Huntington's disease, and Alzheimer's disease
(Walton and Dodd, 2007, and references therein). The mecha-
nisms responsible for the elevation of extracellular glutamate in-
clude enhanced release of glutamate and the reduction of
glutamate uptake (Gilgun-Sherki et al., 2002). This process ap-
pears to involve sustained elevations of intracellular calcium
levels through glutamate transporters, leading to an imbalance
of sodium ions across plasma membranes (Gilgun-Sherki et al.,
2002). Excitatory events may stimulate ROS production, and
there is evidence that ROS can promote additional glutamate
release, generating a vicious amplifying cycle of the neurotoxic
cascade (Mailly et al., 1999; Pellegrini-Giampietro et al., 1990).
Indeed, the vulnerability of glutamate transporters to oxidants
provides evidence that excitotoxicity and oxidative stress are in-
terrelated and act synergistically to induce neuronal damage
(Coyle and Puttfarcken, 1993; Gilgun-Sherki et al., 2002; Trotti et
al., 1998). This concept has general therapeutic implications, as
it suggests that using anti-excitotoxic and antioxidant agents in
combination may improve neuroprotection (Trotti et al., 1998).
The redox activity of selenium-containing molecules has
been suggested to provide antioxidants of considerable potency
(Nogueira et al., 2004; Parnham and Graf, 1991). This has stimu-
lated interest in the synthesis and reactivity of organoselenium
compounds, with particular emphasis on their biological
properties (Engman et al., 1997; Mugesh et al., 2001; Nogueira
et al., 2004). Of particular importance is that the antioxidant
activity of various organoselenium compounds appears to be
related, at least in part, to their glutathione peroxidase (GPx)-
like activity (Mugesh et al., 2001; Nogueira et al., 2004).
Ebselen was the first organoselenium compound suggested
for hydroperoxide-inactivating therapy in thepresence of gluta-
thione (Nogueira et al., 2004). Ebselen has been safely adminis-
tered in several animal models of brain injuries with
pronounced neuroprotective effects (Namura et al., 2001;
Takasago et al., 1997). Based on the encouraging evidence of
the neuroprotective effects of ebselen in animalmodels, clinical
trials were conducted with this compound, obtaining modest
success (Gilgun-Sherki et al., 2002; Yamaguchi et al., 1998).
Diphenyl diselenide (the simplest of the diaryl diselenides) has
been demonstrated to be even more active as a GPx mimic
and less toxic to rodents than ebselen (Meotti et al., 2003;
Wilson et al., 1989). In fact, diphenyl diselenide has a protective
role in a variety of in vitro and in vivo experimental models
associated with the overproduction of free radicals in the
brain, liver, and kidney (Burger et al., 2004; Burger et al., 2006;
Funchal et al., 2006; Ghisleni et al., 2003, 2008; Kade et al., 2009;
Nogueira et al., 2004; Stangherlin et al., 2008).
Several studies havedemonstrated that the extracellular nu-
cleoside guanosine can exert trophic effects on neural cells, as
well as modulate the glutamatergic system (Ciccarelli et al.,
2001; Rathbone et al., 1999; Soares et al., 2004). The mechanism
involved in these effects appears to be related to a stimulatory
effect on glutamate uptake afforded by guanosine (Frizzo
et al., 2001, 2002, 2003; Halliwell, 2006; Margaill et al., 2005;
Schmidt et al., 2005). Indeed, guanosine exhibits protective
effects in a variety of in vitro and in vivomodels of neurotoxicity
that involve the overactivation of glutamate receptors (Frizzo
et al., 2001). In in vitro models, guanosine inhibited glutamateand analogous binding, prevented cell responses to excitatory
amino acids, stimulated the uptake of extracellular glutamate
by astrocyte cultures and brain slices, and protected brain slices
exposed to hypoxia/hypoglycemia (Schmidt et al., 2005, and
references therein). In in vivo models, guanosine protected
against seizures induced by glutamatergic agents in rodents
(Schmidt et al., 2005).
Although antioxidants and purine derivatives are very
promising compounds for the treatment of CNS disorders,
there is no efficient curative treatment that has been proven
effective to date. Thus, combinations of treatments may have
synergistic effects that are more successful. In the present
study, we investigated the protective effects of the combination
of guanosine and 2 organoselenium compounds (ebselen and
diphenyl diselenide) against glutamate-induced oxidative
stress.2. Results
2.1. Lipid peroxidation
Thiobarbituric acid-reactive substance (TBARS) levels in cortical
and hippocampal slices treated with 10mM glutamate were
significantly higher than that observed in control slices
(p<0.05) (Table 1). TBARS levels in striatal slices were not affect-
ed by treatment with any concentration of glutamate (Table 1).
2.2. Cellular viability
Cellular viability was evaluated by measuring the reduction of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) to a formazan product bymitochondrial dehydrogenases.
Glutamate was not able to decrease mitochondrial viability at
any concentration tested in striatal, cortical, and hippocampal
slices (data not shown). Lactate dehydrogenase (LDH) release
can be an index of cytotoxicity, as it is indicative of disruption
of the cellular membrane. Glutamate did not alter LDH release
at any concentration tested in striatal, cortical, and hippocam-
pal slices (data not shown).
2.3. ROS generation
2.3.1. Glutamate×guanosine
Glutamate significantly increased ROS production (2′,7′-
dichlorofluorescin diacetate (DCFH) oxidation) in striatal,
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10 mM (p<0.05, Fig. 1). Guanosine (100 μM) prevented ROS pro-
duction induced by 1 mM glutamate in striatal, cortical, and
hippocampal slices, but could not completely prevent ROS
production when it was induced by 10 mM glutamate
(p<0.05, Fig. 1). Different concentrations of guanosine were
used to prevent DCFH oxidation induced by 1 mM glutamate.
Treatment with 100 and 200 μM guanosine blunted glutamate
(1 mM)-induced ROS production by striatal slices (p>0.05,
Fig. 2A). In cortical and hippocampal slices, guanosine
treatment prevented ROS production at concentrations of 10
and 20 μM, respectively (p<0.05, Figs. 2B, C). Cortical andFig. 1 – Effect of guanosine (100 μM) and glutamate on ROS
production in striatal (A), cortical (B), and hippocampal
(C) slices from rats. Data are expressed as the mean±S.E.M.,
n=6. Experiments were performed in duplicate. Bars with
different letters are significantly different (p<0.05) from each
other. Bars with the letter a are statistically indistinguishable
from the control.hippocampal slices were more sensitive to guanosine than
striatal slices were.
2.3.2. Glutamate×organoselenium compounds
At low concentrations, diphenyl diselenide and ebselen signifi-
cantly prevented glutamate (1 mM)-induced ROS generation inFig. 2 – Effect of guanosine (Gua) on glutamate (Glut)-induced
ROS production in striatal (A), cortical (B), and hippocampal
(C) slices from rats. Data are expressed as the mean±S.E.M.,
n=6. Experiments were performed in duplicate. Bars with
different letters are significantly different (p<0.05) from each
other. Asterisk indicates significant differences from the
control (p<0.05).
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diphenyl diselenide decreased glutamate (1 mM)-induced ROS
production to the control levels at concentrations of 0.5, 0.5,
and 10 μM in striatal, cortical, and hippocampal slices, respec-
tively (p<0.05, Fig. 3). Ebselen prevented glutamate (1 mM)-Fig. 3 – Effect of diphenyl diselenide (DPDS) on glutamate
(Glut)-induced ROS production in striatal (A), cortical (B), and
hippocampal (C) slices from rats. Data are expressed as the
mean±S.E.M., n=6. Experimentswere performed in duplicate.
Bars with different letters are significantly different (p<0.05)
from each other. Asterisk indicates significant differences
from the control (p<0.05).induced ROS production at concentrations of 0.5, 1, and 5 μM in
striatal, cortical, and hippocampal slices, respectively (p<0.05,
Fig. 4).
2.3.3. Glutamate×combined treatment (guanosine+
organoselenium compounds)
Considering that organoselenium compounds act as antioxi-
dants and guanosine could affect glutamate uptake, the use of
both in combination could better protect against glutamate
induced-ROS generation, as they could act via different mecha-
nisms. To test this hypothesis, we investigated whether none-
ffective concentrations of each compound in combination
could exert protective effects against glutamate induced-ROS
generation to avoidanypossible toxic effect causedbyhigh con-
centrations of these compounds. Indeed, the combination of
10 μM guanosine and 1 μM diphenyl diselenide was more
effective in preventing glutamate-induced ROS generation in
striatal, cortical, and hippocampal slices than the individual
compounds alone (p<0.05, Fig. 5). The combination of 100 μM
guanosine with diphenyl diselenide (1 μM) was also effective
in protecting against glutamate-induced ROS production in
striatal, cortical, and hippocampal slices, although this protec-
tion was not different from that exerted by guanosine (100 μM)
and diphenyl diselenide (1 μM) alone (p<0.05, Fig. 5).
The combination of ebselen (1 μM) and guanosine (10 μM)
was better than the individual compounds alone in protecting
against ROS generation induced by glutamate (1 mM) in striatal,
cortical, and hippocampal slices (p<0.05, Fig. 6). Treatment of
striatal, cortical, and hippocampal slices with the combination
of guanosine (100 μM) and ebselen (1 μM) significantly pre-
vented glutamate (1 mM)-induced ROS production, although
these changes were indistinguishable from those caused by
either compound [guanosine (100 μM) and ebselen (1 μM)]
alone (p<0.05, Fig. 6).
2.4. [3H]-Glutamate uptake
Glutamate (1 mM) inhibited [3H]-glutamate uptake in striatal
(44.7% inhibition), cortical (24.9% inhibition), and hippocampal
(41.4% inhibition) slices compared to the intake in control slices
(p<0.05, Fig. 7). Treatment with 10 and 100 μM guanosine
prevented the inhibition of [3H]-glutamate uptake in striatal,
cortical, and hippocampal slices (p<0.05, Fig. 7).3. Discussion
The overstimulation of glutamate receptors triggers a sequence
of cellular events that includes oxidative stress and contributes
to the pathophysiology of a number of brain injuries (Danbolt,
2001; Mejia-Toiber et al., 2006; Walton and Dodd, 2007). In this
Fig. 4 – Effect of ebselen (Ebs) on glutamate (Glut)-induced
ROS production in striatal (A), cortical (B), and hippocampal
(C) slices from rats. Data are expressed as the mean±S.E.M.,
n=6. Experiments were performed in duplicate. Bars with
different letters are significantly different (p<0.05) from each
other. Asterisk indicates significant differences from the
control (p<0.05).
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decreased its uptake in striatal, cortical, and hippocampal slices
from rats, characterizing the primary events of harmful gluta-
matergic overstimulation. Glutamate induced an increase in
TBARS levels in cortical and hippocampal slices only at the
highest concentration tested (10 mM); however, the concentra-
tion of 1 mMused throughout the study did not induce changes
in the TBARS levels. Here, we would like to call attention to the
fact that the TBARS assay is only a global test for assessing lipid
peroxidation because thiobarbituric acid (TBA) is nonspecific for
malondialdehyde (MDA) and can react with nonlipid-related
materials and fatty peroxide-derived decomposition products
other than MDA (Janero, 1990). In this manner, utilization of
the TBARS assay in lipid peroxidation studies requires caution
regarding the interpretation of its results. Glutamate did not in-
duce a loss of viability in the assays performed in this study
(MTT reduction and LDH release), indicating that the slices
were viable during all experiments despite the increase in ROS
levels and the impairment of glutamate uptake. In addition,
we demonstrated that guanosine, ebselen, and diphenyl disele-
nide protected striatal, cortical, and hippocampal slices from
rats from the ROS production evoked by glutamate.
An oxidative stress condition and impairment of glutamate
transport have been observed inparallel in several brainpathol-
ogies leading to acute or chronic neurodegeneration (Trotti
et al., 1998). Amyotrophic lateral sclerosis, Alzheimer's disease,
and ischemic and traumatic injuries are examples of brain
pathologies in which alterations in glutamate transport and
oxidative stress are involved. The toxic pathways by which
exposure to excess glutamate can lead to aberrant ROS forma-
tion include Ca2+-dependent activation of nitric oxide (NO)
synthase, phospholipase A2, and xanthine oxidase (Trotti
et al., 1998). In thismanner, antioxidants are certainly a promis-
ing therapeutic class for the treatment of neurodegenerative
diseases (Halliwell, 2006; Margaill et al., 2005).
Organoselenium compounds have been proposed as poten-
tial therapeutic agents against the formation of free radicals
and thedeleterious actions of ROS secondary to a variety ofneu-
ronal injuries (Centuriao et al., 2005; Nogueira et al., 2004; Posser
et al., 2008; Zhao and Holmgren, 2002). In fact, the neuroprotec-
tive effects of ebselen and diphenyl diselenide have been attrib-
uted to the antioxidant properties of these compounds (Rossato
et al., 2002; Warren, 2002). In addition, it has been reported that
low selenium concentrations in the elderly were significantly
associated with senility and cognitive decline (Berr et al.,
2000). In view of these findings, the protective effects of both
compounds could be related to their ability to prevent the first
signs of glutamate neurotoxicity, such as oxidative stress.
In this study, guanosine was able to prevent the increase in
ROS generation induced by glutamate in striatal, cortical, and
hippocampal slices. These results again demonstrate the rela-
tionship between increased extracellular glutamate and
increased ROS production, as guanosine also protected against
the inhibition of glutamate uptake in all brain regions. In fact,
guanine-based purines such as guanosine are well-known
modulators of the glutamatergic system, and their neuroprotec-
tive effects have been demonstrated in several studies
(Ciccarelli et al., 2001; Frizzo et al., 2001, 2002, 2003; Rathbone
et al., 1999; Schmidt et al., 2005). Therefore, the protective
effects of guanosine observed here could be related with its
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mate uptake into astrocytes (Frizzo et al., 2002; Soares et al.,
2004), subsequently preventing ROS production.
Although antioxidants and purine derivatives have proven
efficiency in counteracting the toxic effects of glutamate, thereare no effective therapeutics for CNS injuries associated with
the overactivation of glutamate receptors to date. Thus, the
combination of antioxidants and purine derivatives could be
more interesting than each compound being used separately
for 2 reasons. Firstly, it would afford protection via different
mechanisms, as the antioxidant would act by attacking the
ROS, whereas guanosinewould act bymodulating the glutama-
tergic system. Secondly, the combination of drugs allows the
use of lower concentrations of each compound. This fact is of
great importance, as one problem with using high doses of
antioxidants is that they can become toxic. Studies have
reported that ebselen at high doses impaired glutamate trans-
mission as part of its toxic effects, and low doses prevent
glutamate-mediated neuronal death associated with its antiox-
idant and/or antiinflammatory properties (Nogueira et al., 2003;
Porciuncula et al., 2001, 2003). In the same manner, diphenyl
diselenide has been demonstrated to exhibit neuroprotective,
antiinflammatory, and antinociceptive activity (Meotti et al.,
2004; Nogueira et al., 2003, 2004), although exposure to high
doses of diphenyl diselenide induces seizure and death in rat
pups and alters glutamatergic homeostasis (uptake and bind-
ing) in vitro and in vivo (Nogueira et al., 2001; Prigol et al., 2007).
Thus, the combination of therapiesmight decrease the dosages
for each agent and consequently reduce the occurrence of
adverse effects (Margaill et al., 2005).
In view of this, themain objective of this study was to inves-
tigate whether the combined use of guanosine and organosele-
nium compounds could be more effective against glutamate-
induced oxidative stress than the individual compounds.
Indeed, the combination of guanosine and organoselenium
compounds prevented glutamate-triggered ROS production in
striatal, cortical, and hippocampal slices. These results corrobo-
rate the idea that the combined treatment is more effective
than the isolated use of each compound. Additionally, a recent
study demonstrated that organoselenium compounds used in
combinationwith guanosine can protect rat brain cortical slices
against methylmercury-induced ROS production related to glu-
tamatergic system disturbances (Roos et al., 2009).
Another point that should be noted is the different
responses of the brain regions to glutamate, guanosine, and
organoselenium compounds. According to our results, cortical
and hippocampal slices were more sensitive to the deleterious
effects of glutamate than striatal slices were, as observed by
the ROS and TBARS production induced by 10mM glutamate.
In addition, the inhibition of glutamate uptake was more pro-
nounced in cortical and hippocampal slices. One explanation
for these differences could be the different concentrations and
distribution of glutamate receptors and transporters among
the brain regions (Erecinska and Silver, 1996; Maiti et al., 2006).
Glutamatergic synapses are more abundant in the cortex and
hippocampus than in the striatum (Lehre et al., 1995). TheseFig. 5 – Effect of the combination of guanosine (Gua) and
diphenyl diselenide (DPDS) on glutamate (Glut)-induced ROS
production in striatal (A), cortical (B), and hippocampal (C) slices
from rats. Data are expressed as the mean±S.E.M., n=6.
Experiments were performed in duplicate. Bars with different
letters are significantly different (p<0.05) from each other. As-
terisk indicates significant differences from the control (p<0.05).
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to glutamate compared to cortical and hippocampal slices.
Moreover, cortical and hippocampal slices were more sensi-
tive to guanosine than striatal slices regarding glutamate-
induced ROS formation, which could also be explained by the
higher glutamatergic activity of these regions. However, the
effects of guanosine on glutamate uptake did not differ among
the brain regions. Therefore, other mechanisms could also be
involved in the ability of guanosine to decrease ROS production.
In addition to the stimulation of glutamate uptake, the decrease
in glutamate binding and the scavenging of hydroxyl radicals
induced by guanosine may also contribute to the protection
and to the different sensitivity observed among the brain
regions (Gudkov et al., 2006; Rubin et al., 1997).
The response of each region to the effect of the organosele-
nium compounds on ROS production varied according to the
concentrations used. The concentrations of organoselenium
compounds necessary to counteract ROS production were
lower in striatal and cortical slices than in the hippocampal
slices. In addition, the combined treatments were less effective
in the striatal slices than in hippocampal and cortical slices,
which could also be a consequence of the differences in the
glutamatergic activity among these brain regions. Although
we attribute the neuroprotection afforded by the organosele-
nium compounds to its antioxidant properties, we cannot rule
out the involvement of other mechanisms.
The discovery and development of potent antioxidant
agents has been one of the most promising approaches in the
search for treatments for CNS injury (Gilgun-Sherki et al.,
2002). Although some of the antioxidants exhibited efficacy in
animal models, most of them did not exhibit beneficial effects
in clinical trials performed to date (Gilgun-Sherki et al., 2002).
The combination of antioxidants and substances capable of
modulating glutamatergic activity would be more effective
than the compounds alone because this combination could di-
minish oxidative stress generated via overactivation of NMDA
receptors and still could diminish excess glutamate in synaptic
clefts (Salom et al., 2004). Our findings supported this idea and
demonstrated that organoseleniumcompounds in combination
with guanosine are promising tools against glutamate-induced
oxidative injury in CNS disorders. Furthermore, additional stud-
ies are necessary to determine the efficacy of the combination
of organoselenium compounds with guanosine in reducing the
prooxidative effects of glutamate in an in vivomodel.4. Experimental procedure
4.1. Materials
[3H]-glutamic acid was purchased from Amersham Biosciences
(Amersham, Bucks, UK). Guanosine, TBA, and MTT wereFig. 6 – Effect of the combination of guanosine (Gua) and
ebselen (Ebs) on glutamate (Glut)-induced ROS production in
striatal (A), cortical (B), and hippocampal (C) slices from rats.
Data are expressed as the mean±S.E.M., n=6. Experiments
were performed in duplicate. Bars with different letters are
significantly different (p<0.05) from each other. Asterisk
indicates significant differences from the control (p<0.05).
Fig. 7 – Effect of guanosine (Gua) and glutamate (Glut) on
[3H]-glutamate uptake in striatal (A), cortical (B), and
hippocampal (C) slices from rats. Data are expressed as the
mean±S.E.M., n=4. Experimentswere performed in duplicate.
Bars with different letters are significantly different (p<0.05)
from each other.
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purchased from Molecular Probes (Eugene, OR, USA). Ebselen
was synthesized with the method described by Engman and
Hallberg (1989). Diphenyl diselenide was synthesized with the
method described by Paulmier (1986). Solutions of organochal-
cogens were prepared freshly in dimethylsulfoxide (DMSO),
and the final concentration of DMSO in the experiments was2%. All other chemicals were of analytical grade and purchased
from local commercial suppliers.
4.2. Animals
Male adult Wistar rats (250–350 g) from our own breeding
colony were kept in cages of 4 animals each. They were placed
in a room with controlled temperature (22±3 °C) on a 12-h
light/dark cycle with lights on at 7:00 a.m. and continuous ac-
cess to food and water. Our institutional protocols on animal
experimentation, which were designed to minimize suffering
and limit the number of animals sacrificed, were followed
throughout the study. All experimentswere conducted inaccor-
dancewith theCommittee onCare andUseof ExperimentalAn-
imal Resources of the Federal University of Santa Maria, Brazil.
4.3. Slice preparation
Animals were sacrificed by decapitation. The brain was quick-
ly removed, placed on ice, and then dissected into 3 specific
regions: the cortex, the hippocampus, and the striatum. Slices
(0.4-mm thick) of the brain regions were rapidly prepared
using a McIlwain Tissue Chopper and then placed in ice-cold
artificial cerebrospinal fluid (ACSF) containing 120 mM NaCl,
5 mM KCl, 1.3 mM MgCl2, 1.5 mM CaCl2, 1.25 mM NaH2PO4,
35 mMNaHCO3, and 10 mM D-glucose. The buffer was bubbled
with 95% O2 and 5% CO2 up to pH 7.4 throughout the
experiments.
4.4. Lipid peroxidation assay
Lipid peroxidation in the cortex, hippocampus, and striatumwas
evaluated by the TBARS method according to Rios and
Santamaria (1991). The slices (5) were preincubated with L-gluta-
mate (0.01, 0.1, 1, and 10mM) for 2 h in oxygenated ACSF. For
the TBARS assay, the slices were homogenized in 500 μL of ice-
cold ACSF, and 1mL of the TBA reagent (15% trichloroacetic
acid, 0.375% TBA, and 2.5% v/v HCl) was added. After 30min of
incubation, samples were centrifuged (3000×g, 15 min), and the
TBARS levels were measured at 532 nm in the supernatant. The
final amounts of TBARS,mostlyMDA,were calculated by interpo-
lation of values in an MDA standard curve and corrected by the
content of protein per sample. The results were calculated as
nmol of TBARS/mg of protein and expressed as percent of
controls.
4.5. Cellular viability assay
Cellular viability in the cortex, hippocampus, and striatum
was quantified by measuring the reduction of MTT to a dark
violet formazan product by mitochondrial dehydrogenases
(Mosmann, 1983). The slices (2) were incubated with L-gluta-
mate (0.01, 0.1, 1, and 10 mM) for 2 h in oxygenated ACSF.
After incubation, the slices were washed twice with 1 mL of
ACSF. The MTT reduction assays were performed in plates
containing 1 mL of ACSF, and the reaction was started by add-
ing 0.5 mg/mL MTT. After 1 h of incubation at 37 °C, the medi-
um was removed, and the precipitated formazan in the slices
was solubilized in DMSO. The rate of MTT reduction was
measured spectrophotometrically at 570 nm. The results
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4.6. LDH release assay
LDH release, an index of cell disruption, was assessed in slices
of the cortex, hippocampus, and striatum. The slices (2) were
incubated with L-glutamate (0.01, 0.1, 1, and 10mM) by 2 h in
oxygenated ACSF. After this period, the total incubation
medium of the slices (1 mL) was removed andmixedwith reac-
tion medium containing 100 mM glycine–KOH buffer (pH 10),
50 mM lactate, and 1 mM NAD+. The enzyme activity was
measured by determining the amount of NADH formed at
room temperature at 340 nm (Pereira et al., 1991). Total LDH
activity was determined by the same procedure described
above after adding a final concentration of 10% Triton X-100
and disrupting the slice by homogenization. LDH leakage was
estimated as the ratio between the LDH activity in the incuba-
tion medium and that of the whole slice content. The results
were expressed as percent of LDH activity with respect to
control values.
4.7. Estimation of ROS generation
Generation of ROS was estimated with the fluorescent probe
DCFH by the method described by Ali et al. (1992). Slices (2) of
the cortex, hippocampus, and striatum were preincubated
with 100 μM guanosine in oxygenated ACSF for 15min at
37 °C. Then, L-glutamate (0.01, 0.1, 1, and 10mM) was added to
the slices and incubated for another 2 h in order to create a
dose–response curve ofDCFHoxidation. The glutamate concen-
tration of 1 mM was used to perform the other experiments
with guanosine and organoselenium compounds because it
was the lowest concentration of glutamate that significantly
induced ROS generation (DCFH oxidation), which is supported
by other studies (Kannurpatti, et al., 2004; Molz, et al., 2011).
Then, we performed dose–response curve of DCFH oxidation
with L-glutamate (1 mM) versus guanosine (0.5–200 μM), diphe-
nyl diselenide (0.05–100 μM), and ebselen (0.01–100 μM). To
study the effect of the combination of guanosine and organose-
lenium compounds, the concentrations of 10 and 100 μM were
chosen for guanosine, and 1 μMwas chosen for diphenyl disele-
nide and ebselen. For the DCFH oxidation assay, the slices were
homogenized in 2.5 mL of saline solution (0.9% NaCl). Aliquots
of 2.5 mL were incubated in the presence of DCFH (5 μM) at
37 °C for 1 h. Fluorescence was measured using excitation and
emission wavelengths of 488 and 522 nm, respectively. A
calibration curvewas establishedwith standardDCF. ROS levels
were expressed as percent of control as follows: (F−Fo)/Fo⁎100,
where F is the fluorescence intensity of the control slices and Fo
is the fluorescence intensity of the slices treated with
glutamate, guanosine, and/or organoselenium compounds.
The data with organoselenium compounds alone was omitted
because they did not exert any effect per se on the fluorescence
measurements (DCFH fluorescence).
4.8. [3H]-glutamate uptake assay
For the glutamate uptake measurement, slices (2) of the cortex,
hippocampus, and striatum were preincubated with andwithout 10 and 100 μM guanosine in oxygenated ACSF during
15 min at 37 °C. Then, 1 mM L-glutamatewas added to the slices
and incubated for another 2 h. At the end of the incubation pe-
riod, the slices were washed twice with ACSF and adjusted to
pH 7.2. Glutamate uptake was performed according to Frizzo
et al. (2002) with some modifications. Briefly, uptake was per-
formed at 35 °C by adding 100 μM unlabeled L-glutamate and
1 μM (0.33 μCi/mL) [3H]-glutamate. The reaction was stopped
after 7 (cortex), 5 (hippocampus), or 3 (striatum)min bywashing
twicewith 1 mLof coldACSF, immediately followedby the addi-
tion of 0.5 N NaOH, which was kept overnight. Sodium-
independent uptake was determined using choline chloride in-
stead of sodium chloride, which was subtracted from the total
uptake to obtain the sodium-dependent uptake. Incorporated
radioactivity was determined with a Packard scintillator (TRI
CARB 2100 TR—PerkinElmer, Waltham, MA, USA).
4.9. Protein measurement
Protein concentrations were assayed by the method of Lowry
et al. (1951) with bovine serum albumin as the standard.
4.10. Statistical analysis
Data were analyzed statistically by 1-way ANOVA, followed by
Duncan's post-hoc tests. The resultswere considered statistically
significant when p<0.05.Acknowledgments
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